Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06029166
Other study ID # 22-0252
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 1, 2023
Est. completion date October 1, 2026

Study information

Verified date July 2023
Source University Hospital, Caen
Contact Joachim Alexandre, MD, PhD
Phone +33 2.31.06.46.71
Email alexandre-j@chu-caen.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to screen all types of electrocardiographic changes and rhythm disorders in adult patients with a hematologic malignancy requiring a treatment by Bruton's tyrosine kinase (BTK) inhibitor (ibrutinib, acalabrutinib, zanubrutinib) using an insertable subcutaneous cardiac monitor (ISCM) and occurring from inclusion and within 12 months. This study consists of the implantation of an ISCM at inclusion and before BTK inhibitor initiation. Then patients will have medical visits every 3 months (+/- 7 days) during 12 months and a continuous cardiac telemonitoring using the ISCM.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date October 1, 2026
Est. primary completion date October 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients, - Definite diagnosis of hematologic malignancy requiring a BTK inhibition with ibrutinib, acalabrutinib or zanubrutinib, - Expected BTK inhibitor duration estimated to be at least 12 months, - Sinus rhythm at enrolment, - Willing to sign patient consent form and to comply with scheduled visits, as outlined in the protocol Exclusion Criteria: - Age < 18 years old, - Adults with protective measures (curatorship or tutorship) and vulnerable patients, - Pregnant or nursing women, - Permanent atrial fibrillation or long-standing persistent atrial fibrillation as defined by the European Society of Cardiology guidelines, - Atrial fibrillation on the electrocardiogram at the inclusion visit, - Previous left atrial ablation or previous maze or maze-like surgery, - Indication for or patients with a pacemaker or implantable cardioverter-defibrillator at baseline, - Untreated hyperthyroidism, - Uncorrected kaliaemia disorders at the inclusion visit, - Hemoglobin < 8 g/L at the inclusion visit, - Thrombopenia < 50,000/mm3 at the inclusion visit, - Active bleeding, - Myocardial infarction < 1 month, - Surgery < 1 month, - Mechanical heart valve, - Valvular heart disease requiring surgery, - Inability to follow the required procedures of the clinical investigation plan, - No signature of patient consent form.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)
Implantation of a subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®) before beginning the Bruton's tyrosine kinase inhibitor treatment.

Locations

Country Name City State
France Caen University Hospital, Department of Pharmacology Caen Normandie

Sponsors (9)

Lead Sponsor Collaborator
University Hospital, Caen Biotronik SE & Co. KG, Centre Hospitalier Universitaire de Saint Etienne, European Georges Pompidou Hospital, Groupe Hospitalier Pitie-Salpetriere, Hôpital Necker-Enfants Malades, Hospices Civils de Lyon, Saint Antoine University Hospital, University Hospital, Marseille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of any electrocardiographic changes and/or rhythm disorders from first BTK inhibitors prescription to 12 months of follow-up, symptomatic or not, detected on 12-lead ECG and/or on ISCM. Electrocardiographic changes and/or rhythm disorders are defined by the European Society of Cardiology guidelines. 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days)
Secondary Electrocardiographic intervals (PR, QRS, QT) measurements on both 12-lead ECG and ISCM at baseline and with BTK inhibitors exposure. 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days)
Secondary The occurrence of bleeding events from inclusion and within 12 months. 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days)
Secondary Correlation between IRAF and multiple demographic, clinical, cardiac imaging (morphological data) and serum cardiac biomarkers. 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days)
Secondary IRAF management. 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days)
Secondary Progression-free survival of patients treated by BTK inhibitors according to the presence of IRAF. 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days)
Secondary Correlation between QT/QTc measurements performed by ISCM (BIOMONITOR IIIm®, Biotronik®) and a QT expert on 12-leads ECG. 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days)
Secondary Daily body temperature monitoring with the ISCM (BIOMONITOR IIIm®, Biotronik®) temperature sensor and will be compared with conventional body temperature measurements performed during follow-up visits. 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days)
Secondary Constitute a plasmatic biobank for futures ancillary studies. 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days)
Secondary The need for ISCM (BIOMONITOR IIIm®, Biotronik®) remove within the 12-months follow-up. 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days)
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A